Status:

UNKNOWN

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Lead Sponsor:

Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions:

Advanced Clear Cell Renal Cell Carcinoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer

Detailed Description

This study is a single arm, non-randomized, multicenter, open label, phase 2 clinical trial to evaluate preliminary efficacy and safety in patients with advanced clear cell renal cacer

Eligibility Criteria

Inclusion

  • Voluntarily participate in the study and sign the informed consent.
  • Advanced clear cell renal cancer.
  • At least one measurable tumor target lesion.
  • Life expectancy≥3 months.
  • Suitable organ functions.
  • Patients who had failed at least one line therapy.
  • ECOG 0-1.
  • The samples of tumor tissue should be provided

Exclusion

  • Patients who had received anti-tumor therapy/radiotherapy/immunotherapy within 4 weeks.
  • History of other malignant tumors within 5 years.
  • Patients with CNS metastasis.
  • History of active autoimmune diseases.
  • Patients with poor-controlled systemic diseases after treatment.
  • Patients with severe infection or requiring antibiotic treatment within 4 weeks before dosing.
  • Adverse reactions related to previous treatments failed to recover to CTCAE 5.0 ≤1
  • Patients who had experienced immune-related adverse events (irAE) with grade 3 or above.
  • Patients who were allergic to any composition of experimental drug.
  • Subjects with poor treatment compliance.
  • Pregnant or lactating woman.
  • Live vaccination within 28 days before first dosing.
  • History of drug abuse or addiction
  • Patients with active HBV or HCV, or HIV antibody positive,or Tp-Ab positive.

Key Trial Info

Start Date :

September 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2024

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05440045

Start Date

September 1 2022

End Date

September 1 2024

Last Update

August 17 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Clinical Study of 6MW3211 in Patients With Renal Cancer | DecenTrialz